P036 Bisphosphonates (Bis) combined with sunitinib (Su) may improve the response rate (RR), progression free survival (PFS) and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

✍ Scribed by Keizman, D.; Ish-Shalom, M.; Maimon, N.; Gottfried, M.; Peer, A.; Neumann, A.; Hayat, H.; Boursi, B.; Kovel, S.; Sella, A.; Pili, R.; Hammers, H.; Sinibaldi, V.; Eisenberger, M.; Berger, R.; Carducci, M.

• Book ID: 122023285
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 58 KB
• Volume: 11
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/S1569-9056(13)60413-3